US FDA Gets Earful On Biologic ‘Umbrella’ Exclusivity, Patent Listings, Biosimilar Bridging Study Waivers

 
• By Sue Sutter
Man with hearing problem on grey background, closeup
US FDA heard plenty of feedback from industry trade groups on issues involving biosimilar competition and product innovation.

More from Biosimilars

More from Biosimilars & Generics